Patent details

LUC50041 Product Name: Glycoprotéine F du sous-groupe A du VRS stabilisée dans la conformation pré-fusion et glycoprotéine F du sous-groupe B du VRS stabilisée dans la conformation pré-fusion

Basic Information

Publication number:
LUC50041
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP168164051
Legal Status:
Pending & Published
Application number:
LUC50041
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/23/1752
Marketing Authorization Type:
Marketing Authorization Date:
24/08/2023
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
24/02/2026
First Marketing Authorization date:
24/08/2023
Grant date:
Activation date:
Publication date:
25/02/2026
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
24/08/2038
SPC Extension Expiration:
24/08/2038
Rejection date:
Withdrawal date:

Owner

From:
24/02/2026
 
 

Name:
Pfizer Inc.
Address:
66 Hudson Boulevard East, New York, NY 10001-2192, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
24/02/2026
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

Bulletin Heading:
SPC1
Bulletin edition number:
2026/04
Publication date:
03/03/2026
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

Annual Fees

Annual Fee Due Date:
31/12/2036
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
24/02/2026 Application Form 5
24/02/2026 General Document 3
24/02/2026 General Document 36
24/02/2026 General Document 9
24/02/2026 Outgoing Correspondence 2
24/02/2026 General Document 1
25/02/2026 Outgoing Correspondence 1
25/02/2026 Publication 1